Clinical Trials Browser

Phase 1/2 × Recruiting × Pluvicto × Clear all

NCT07226986 2026-04-16

A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC

PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy

NCT05113537 2026-04-13

UPLIFT

Phase 1/2 Recruiting

30 enrolled

Genitourinary

Prostatic Neoplasms

NCT06785636 2026-04-07

P300

Phase 1/2 Recruiting

252 enrolled

Genitourinary

Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Male Urogenital Diseases

NCT06574880 2025-11-24

STARLiT

Phase 1/2 Recruiting

45 enrolled

Genitourinary

Prostatic Neoplasms